The chemical class designated as ST7 Activators encompasses a diverse group of compounds that can influence various cellular signaling pathways and processes, with the outcome of modulating the activity of the ST7 protein. These activators can operate through different mechanisms, such as inhibition of specific kinases, modulation of gene expression, and alteration of cellular stress responses. By targeting these pathways, ST7 Activators can play a role in regulating the functions associated with the ST7 gene, which includes effects on cell adhesion, signal transduction, and genomic stability. Through the inhibition of kinases like PI3K, MEK, or p38 MAPK, these activators can indirectly influence the activity of ST7 by altering the balance of cellular signaling, leading to changes in cell growth, differentiation, and survival. Additionally, by affecting transcriptional regulation through histone deacetylation or DNA methylation, these compounds can alter gene expression patterns that can affect the function of ST7.
Furthermore, the chemical class of ST7 Activators can include molecules that affect cellular responses to DNA damage, such as the inhibition of PARP, which can lead to an increased demand for DNA repair mechanisms and possibly activate ST7-related pathways. Other members of this class can interact with cellular machinery that controls the cell cycle, possibly having an effect on the expression or function of ST7. The diversity within this chemical class is reflected in the range of molecular targets they interact with, from surface receptors to nuclear enzymes, illustrating the complex interplay between small-molecule activators and the cellular environment. The ability of these compounds to modulate such a broad spectrum of biological processes underscores the intricate nature of cellular regulation and the multifaceted role that ST7 might play in cellular homeostasis.
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that could possibly activate ST7 by affecting signal transduction pathways involving cell cycle control and apoptosis. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that could possibly activate ST7 by affecting cellular stress response pathways and potentially enhancing genomic stability. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
An inhibitor of JNK that could possibly activate ST7 by modulating signaling pathways related to apoptosis and cell cycle arrest. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor that could possibly activate ST7 by affecting the MAPK/ERK pathway and its role in growth and apoptosis. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor that could possibly activate ST7 by disrupting signal transduction pathways that control cell growth and survival. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that could possibly activate ST7 by affecting cell cycle progression and protein synthesis. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
A DNA methyltransferase inhibitor that could possibly activate ST7 by demethylating DNA and promoting the expression of tumor suppressor genes. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Another histone deacetylase inhibitor that could possibly activate ST7 by altering gene expression patterns and enhancing tumor suppressor functions. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $56.00 $212.00 $764.00 | 24 | |
An MDM2 antagonist that could possibly activate ST7 through p53-mediated signaling pathways by increasing p53 activity. | ||||||
Veliparib | 912444-00-9 | sc-394457A sc-394457 sc-394457B | 5 mg 10 mg 50 mg | $178.00 $270.00 $712.00 | 3 | |
A PARP inhibitor that could possibly activate ST7 by increasing the need for DNA repair mechanisms in which ST7 might be involved. |